Multi-cancer early detection
GRAIL is a healthcare company focused on multi-cancer early detection (MCED) through its Galleri blood test, leveraging next-generation sequencing, machine learning, and large-scale clinical studies. Headquartered in Menlo Park, it aims to change the cancer trajectory by detecting deadly cancers early when more treatable.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
